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ABSTRACT
Little progresses have been made in the treatment of glioblastoma (GBM), the 
most aggressive and lethal among brain tumors. Recently we have demonstrated that 
Chloride Intracellular Channel-1 (CLIC1) is overexpressed in GBM compared to normal 
tissues, with highest expression in patients with poor prognosis. Moreover, CLIC1-
silencing in cancer stem cells (CSCs) isolated from human GBM patients negatively 
influences proliferative capacity and self-renewal properties in vitro and impairs the 
in vivo tumorigenic potential. Here we show that CLIC1 exists also as a circulating 
protein, secreted via extracellular vesicles (EVs) released by either cell lines or GBM-
derived CSCs. Extracellular vesicles (EVs), comprising exosomes and microvesicles 
based on their composition and biophysical properties, have been shown to sustain 
tumor growth in a variety of model systems, including GBM. Interestingly, treatment 
of GBM cells with CLIC1-containing EVs stimulates cell growth both in vitro and in vivo 
in a CLIC1-dose dependent manner. EVs derived from CLIC1-overexpressing GBM cells 
are strong inducers of proliferation in vitro and tumor engraftment in vivo. These 
stimulations are significantly attenuated by treatment of GBM cells with EVs derived 
from CLIC1-silenced cells. However, CLIC1 modulation appears to have no direct role 
in EV structure, biogenesis and secretion. These findings reveal that, apart from the 
function of CLIC1 cellular reservoir, CLIC1 contained in EVs is a novel regulator of 
GBM growth.
INTRODUCTION
Glioblastoma (GBM) is the most aggressive among 
tumors of glial origin and represents, with a median patient 
survival of 14 months, a social and economic burden [1, 2]. 
The complexity in the study of GBM resides in its extremely 
heterogeneous nature at both the cellular and molecular 
levels. GBM is composed by a subpopulation of cancer stem 
cells (CSCs) able to fuel and sustain tumor development 
and progression, as well as tumor cells and non-neoplastic 
parenchymal cells, comprising vascular cells, microglia, 
peripheral immune cells, deeply intermingled throughout the 
tumor mass [3–5]. All these cells communicate with each 
other via the secretion and uptake of a number of factors that 
play a pivotal role in controlling the course of pathology. 
Among these, secreted extracellular vesicles (EVs) are a 
class of small bilayered particles (50–150 nm in size) that 
have been extensively studied in a variety of model systems 
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for their ability to transfer their molecular cargoes to target 
cells, both locally and at a distance, influencing the tumor 
phenotype [6–8].
The first member of Chloride Intracellular 
Channel family (CLIC), namely CLIC1, holds 
pathological implications in a variety of different 
tumoral contexts [9–12], being involved in cell cycle 
progression [13, 14], cell motility regulation [15–18], 
resistance to pharmaceutical compounds [19]. We have 
recently demonstrated that CLIC1 is functionally active 
as a chloride channel in GBM CSCs and that inhibition of 
CLIC1, either by gene silencing using RNA interference 
or by in vitro incubation with a blocking antibody, slows 
GBM CSC proliferation and self-renewal and reduces 
in vivo tumorigenicity [20]. The recent identification of 
CLIC1 outside the cellular environment, in biological 
fluids like plasma [21] and serum [22, 23], urine [24] and 
in the medium of different cell lines often in association 
with secreted EVs [25–31], fostered the hypothesis that a 
circulating CLIC1 protein is detectable in the context of 
brain tumors in association to EVs, and it might potentiate 
the function of CLIC1 intracellular reservoir as a novel 
regulator of GBM growth.
RESULTS
CLIC1 protein is secreted by GBM cells in vitro
CLIC1 was recently identified by proteomic screens in 
the supernatants of various cell lines and in human fluids (i.e 
serum, plasma, urine) [21–24]. These intriguing observations 
prompted us to examine the possibility that CLIC1 protein 
could be released also by GBM cells. CLIC1 protein was 
expressed in the cell lysates of all GBM cell lines analyzed 
as well as in their conditioned media (Fig. 1A). The culture 
medium was devoid of GAPDH, suggesting that CLIC1 
extracellular release was not a consequence of contamination 
by intracellular proteins (Fig. 1A). Moreover, cell viability 
measured by incorporation of propidium iodide (PI) was 
greater than 95%, indicating that CLIC1 release was not due 
to cell death (Fig. S1).
To further confirm CLIC1 protein release by 
GBM cells, we employed U87 MG cells overexpressing 
CLIC1 protein fused to Green Fluorescent Protein (GFP) 
at the N-terminal end (U87 CLIC1 GFP). 24 hours 
after cell plating, we collected culture medium and 
immunoprecipitated GFP-tagged CLIC1 protein. A single 
band of 50 kDa corresponding to CLIC1 GFP fusion 
protein was detected in the medium from U87 CLIC1 GFP 
cells, while no band was detected in the medium from 
mock transfected cells, confirming that exogenous CLIC1 
GFP protein was released in the medium (Fig. 1B).
As a complementary approach, we co-cultured U87 
MG cells expressing the FLAG-tagged isoform of CLIC1 
(U87 CLIC1 FLAG) with U87 MG cells expressing Green 
Fluorescent Protein (U87 GFP). After 24 hours, we detected 
by immunofluorescence FLAG-tagged isoform of CLIC1 on 
U87 GFP cells (Fig. 1C), indicating that CLIC1 protein had 
been transferred from cell to cell. Collectively, these results 
demonstrate that CLIC1 protein is secreted by GBM cells 
in vitro and it is internalized by recipient cells.
CLIC1 protein is secreted via extracellular 
vesicles (EVs)
We then investigated the mechanism of CLIC1 
protein release from GBM cells. Interestingly, CLIC1 
protein encloses two structural features indicative of a 
vesicle-mediated secretion: a PPXY motif for binding of 
Nedd4 type E3 ubiquitine ligases and a dileucine cluster 
motifs [32]. Notably, Nedd4-mediated ubiquitination is 
responsible for ubiquitinated protein sorting to specific 
endosome compartments prior to vesicle budding [33]. 
Of note, CLIC1 protein is ubiquitinated in GBM cells, as 
shown by immunoprecipitation with anti-CLIC1 antibody 
and immunoblot with antiubiquitin antibody (Fig. S2). In 
agreement, analysis of ExoCarta database revealed that 
CLIC1 protein resides in extracellular vesicles (EVs), 
comprising both exosomes and shedded microvesicles, 
released from different cell types [27]. To investigate 
whether CLIC1 secreted protein is contained in EVs from 
GBM cells, we selected U87 MG cells, which are known 
to produce significant amounts of EVs [8]. EVs were 
isolated from U87 MG conditioned media according to an 
established protocol based on serial centrifugation [34]. 
Nanoparticle Tracking Analysis (NTA) revealed the presence 
of an heterogeneous population of vesicles, with an average 
mean diameter of 146 nm (Fig. 2A), and comprising vesicles 
smaller than 50 nm (2,8% of the total), vesicles ranging in 
size from 50 to 100 nm (22,8% of the total) or from 100 to 
150 nm (40,2% of the total), and vesicles larger than 150 nm 
(34,1% of the total) (Fig. 2B). Electron microscopy showed 
heterogeneous vesicles (Fig. 2C, upper panel) positive for 
CD63, a tetraspanin strongly enriched in late endosomes 
and exosomes (Fig. 2C, lower panel) [35]. Purified EVs 
were enriched in the exosome specific proteins CD63 
and tsg101 (tumor susceptibility gene 101), as shown by 
immunoblotting analysis, while whole cell lysates were 
immuno-negative for both proteins (Fig. 2D). Notably, 
GM130 cis-Golgi marker was absent, demonstrating the 
purity of the isolated fractions (Fig. 2D). Interestingly, 
CLIC1 protein was expressed in EVs derived from U87 
MG cells, as demonstrated by both immunoblot analysis 
(Fig. 2D) and immuno-electron microscopy (Fig. 2E). 
CLIC1 protein was also expressed in EVs derived from two 
other GBM cell lines (i.e. U118 MG and T98G) (Fig. 2D).
We next visualized the co-localization between 
CLIC1 and CD63 protein at the cellular level, by in situ 
proximal ligation assay (PLA) [36]. PLA revealed that 
a substantial fraction of CLIC1 protein was located 
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in CD63-positive compartments of the cell, further 
supporting CLIC1 sorting to EVs (Fig. 2F and S3A). The 
possibility that PLA signals derived from non-specific 
binding of PLA probes was excluded by the absence of 
PLA fluorescence in CLIC1-silenced cells (Fig. S3B). 
Taken together, our data provide evidence that CLIC1 
protein is secreted from GBM cells in EVs.
CLIC1-containing EVs regulate the proliferative 
response of GBM cells
We previously described the role of CLIC1 protein 
in GBM progression through the modulation of GBM CSC 
self-renewal and proliferation [20]. Here, we sought to 
determine whether CLIC1-containing EVs are internalized 
Figure 1: CLIC1 protein is secreted by glioblastoma cells. A. CLIC1 expression was analyzed by Western blot in cell lysates 
(left panel) and conditioned media (right panel) of several GBM cell lines. GAPDH was used as loading control. A representative 
immunoblot is shown. B. U87 MG cells were mock infected or infected with CLIC1 GFP fusion protein. Cells lysates and conditioned 
media were immunoblotted (Input), or immunoprecipitated against GFP-tag (IP anti-GFP) and then immunoblotted with CLIC1 antibody. 
A representative immunoblot is shown. C. U87 MG cells expressing Green Fluorescent Protein (GFP) were co-cultured with U87 MG cells 
expressing the FLAG-tagged isoform of CLIC1 for 24 hours. Cells were stained using anti-FLAG antibody (red). Arrowheads mark FLAG-
tagged isoform of CLIC1 on U87 MG GFP cells. Scale bar, 20 μm.
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by recipient cells and influence the proliferative response 
of GBM cells. To this end, we labeled U87 MG cell-
derived EVs with the lipid-associating fluorescent dye 
PKH26. When PKH26-positive EVs were incubated with 
human embryonic kidney 293T cells, we observed a rapid 
uptake of labeled EVs into the recipient cells, as indicated 
by confocal microscopy (Fig. S4A) and flow cytometry 
(Fig. S4B). Labeled EVs displayed a time-dependent 
Figure 2: CLIC1 protein is secreted by GBM cells via Evs. A. Size profile of EVs released by U87 MG cells measured by NTA. 
Shown the profile from a representative experiment. B. EVs were divided into four different dimensional classes, and their abundance was 
measured by NTA. Shown the profile from a representative experiment. C. Representative transmission electron micrograph of GBM cell-
derived EVs (100 nm EVs, white arrow; 40 nm EVs, black arrows, Upper). Representative immuno-EM image of CD63 staining of GBM 
cell-derived EV (Lower). Scale bar, 100 nm. At least 200 EVs from 10 sections were examined in two independent experiments. D. Whole 
cell lysates (WCL) from different GBM cell lines and lysates from corresponding EVs were analysed for the indicated proteins by Western 
blotting. A representative immunoblot is shown. E. Representative immuno-EM image of GBM cell-derived EVs. Double-staining was 
conducted using anti-CD63 antibody (10 nm gold particles, indicated by arrowheads) and anti-CLIC1 antibody (15 nm gold particles, 
indicated by arrows) Scale bar, 110 nm. At least 300 EVs from 30 sections were examined in three independent experiments. F. CLIC1 
and CD63 colocalization was assessed in U87 MG cells by in situ proximal ligation assay (PLA). Scale bar, 20 μm. At least 10 cells from 
5 sections were examined in three independent experiments.
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uptake kinetic, which reached the maximum 24 hours 
after incubation, when PKH26 fluorescence was observed 
in nearly 80% of recipient cells (Fig. S4B and S4C). 
Moreover, incubation at 4°C significantly reduced EV 
uptake (Fig. S4D).
To assess the effects of CLIC1-containing EVs on 
GBM cell growth, we silenced CLIC1 (U87 MG siCLIC1) 
or overexpressed a FLAG-tagged version of CLIC1 (U87 
MG CLIC1 FLAG) (Fig. 3A) in U87 MG cells, which 
express endogenous CLIC1. We collected conditioned 
media from the same amount of control (U87 MG NT), 
U87 MG siCLIC1 and U87 MG CLIC1 FLAG cells and 
isolated EVs through serial centrifugations. Immunoblot 
analysis confirmed the modulated expression of CLIC1 
in EVs derived from the three cell lines (Fig. 3A). 
Notably, CLIC1 expression level in EVs mirrored CLIC1 
intracellular level (Fig. 3A). Moreover, the three EV 
groups expressed similar levels of the known exosomal 
markers CD63 and tsg101 (Fig. 3A). Functionally active 
EVs isolated from either U87 MG NT, U87 MG siCLIC1 
and U87 MG CLIC1 FLAG cells were added to U87 
MG recipient cells and cell proliferation was evaluated. 
Consistent with a previous report of growth stimulation 
induced by EVs on GBM cells [8], exposure of U87 MG 
cells to EVs isolated from U87 MG NT cells resulted in 
increased proliferation. Administration of an equal amount 
of EVs isolated from U87 MG CLIC1 FLAG cells showed 
a robust proliferative response of U87 MG recipient cells 
compared to untreated cells. Intriguingly, EV-mediated 
mitogenic stimulation was strongly impaired upon 
treatment with EVs derived from U87 MG siCLIC1 cells 
(Fig. 3B). Altogether, these data demonstrate that CLIC1-
containing EVs modulate GBM proliferative response in 
a CLIC1-dependent fashion.
CLIC1-containing EVs enhance GBM growth 
in vivo
To assess whether the effect of CLIC1-containging 
EVs occurred also in vivo, we injected U87 MG cells with 
NT EVs, siCLIC1 EVs and CLIC1 FLAG EVs, or PBS 
as control, subcutaneously into one flank of nude mice 
and monitored tumor growth over time. In agreement 
with the in vitro results, we observed a marked increase 
in tumor growth when we added NT EVs to the cells. 
Interestingly, co-injection of U87 MG cells with EVs 
isolated from U87 MG CLIC1 FLAG cell cultures resulted 
in a massive increase in tumor growth. On the contrary, 
the co-injection of U87 MG cells with EVs isolated from 
U87 MG siCLIC1 cells resulted in total abrogation of 
such enhancement (Fig. 4A). Approximately 3 weeks 
after cell implantation, we surgically resected the tumors 
and weighted them. As shown in Fig. 4B, the mean tumor 
weights were significantly higher in mice bearing tumors 
derived from U87 cells treated with CLIC1 FLAG EVs 
(Fig. 4B).
We next established orthotopic xenografts by 
injecting U87 MG cells together with NT EVs, siCLIC1 
EVs, CLIC1 FLAG EVs, or PBS as control into brains of 
nude mice. Mice were sacrificed after one and three weeks 
and tumor incidence evaluated. The results indicated that 
EVs enriched in CLIC1 protein (NT EVs and CLIC1 
FLAG EVs), but not those with low-CLIC1 content 
(siCLIC1 EVs), formed tumors with higher incidence 
(Table 1). These results collectively suggest that CLIC1 
modulation influences EV-mediated tumorigenic potential 
of GBM cells.
CLIC1 protein is contained in GBM Stem Cells-
derived EVs
GBM is maintained by a sub-population of 
CSCs which survive traditional therapies, allowing 
tumor regrowth, and explains the intratumoral cellular 
heterogeneity typical of this tumor [37]. We verified 
whether CLIC1 protein could be secreted from GBM 
CSCs, and whether its release occurred via EVs. GBM 
CSCs were isolated from human patient-derived GBMs 
and cultured in serum-free medium [38]. Examination 
of conditioned medium after 48 hour-cultures revealed 
that GBM CSCs secrete CLIC1 protein (Fig. 5A). 
Notably, CLIC1 was not released in the medium as a 
consequence of cell death, as demonstrated by the 
absence of GAPDH in the culture medium (Fig. 5A) 
and by the low percentage of cell death measured by the 
method of PI incorporation (Fig. S5). Next, we isolated 
EVs from the conditioned medium of GBM CSCs. The 
size of the isolated EVs was confirmed by NTA and 
ranged from 50 nm to 220 nm, with a mean value of 
120 nm (Fig. 5B). Immunoblot analysis performed on 
EV extracts confirmed the enrichment of the exosomal 
markers CD63 and tsg101 and the lack of expression of 
GM130 cis-Golgi marker compared to the corresponding 
whole cell lysates (Fig. 5C). In agreement with data 
obtained from GBM cell lines, we confirmed that 
CLIC1 protein was expressed in GBM CSCs-derived 
EVs (Fig. 5C). The presence of CLIC1 in EVs was 
confirmed in CSCs established from a different GBM 
patient (Fig. S6). To investigate the role of CLIC1 in 
GBM CSC-derived EVs, we silenced CLIC1 expression 
in GBM CSCs (siCLIC1GBM CSCs) and purified 
EVs from culture medium by serial centrifugation. We 
observed a significant decrease of CLIC1 protein content 
in either siCLIC1GBM CSCs and in the corresponding 
EVs (siCLIC1 EVs) (Fig. 5D and S6). To determine 
the effect of CLIC1 reduction in EVs secreted by 
GBM CSCs, we incubated GBM CSCs with NT EVs 
and siCLIC1 EVs released by control GBM CSCs and 
siCLIC1 GBM CSCs, respectively. In agreement with 
the results obtained with GBM cells lines, CLIC1 
depletion in EVs resulted in the reduction of GBM 
CSCs growth compared to control (Fig. 5E and S6). 
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In the same way, intracranial injection of GBM CSCs 
treated with siCLIC1 EVs resulted in a significant 
reduction of tumor incidence at the early time point 
analyzed (i.e. 2 weeks after cell injection) (Table 2). 
Unexpectedly, the fact that all mice developed tumors at 
the end point of the experiment (i.e. 4 weeks after cell 
Figure 3: CLIC1-containing EVs regulate the proliferative response of GBM cells. A. Whole cell lysates (WCL) obtained 
from U87 MG control cells (NT), CLIC1 silenced cells (siCLIC1) and CLIC1 overexpressing cells (CLIC1 FLAG), as well as lysates of 
corresponding EVs, were analysed by Western blotting using antibodies against CLIC1, and the EV markers CD63 and tsg101. Vinculin 
was used as loading control. A representative immunoblot is shown. B. U87 MG cells were incubated with EVs (50 μg/ml) derived from 
U87 MG NT, U87 MG siCLIC1 and U87 MG CLIC1 FLAG cells, or PBS as control (veichle). Cell growth was measured 72, 96 and 
120 hours after EV administration. Three independent experiments were performed; error bars represent standard error; 
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injection) reflects a delay in tumor formation in the early 
fase of GBM growth (Table 2).
CLIC1 modulation in the cell does not alter EV 
phenotypic features and release
We next sought to define whether the difference 
in EV stimulatory capacity might be due to changes in 
EV characteristics. EVs purified from the same number 
of U87 MG NT, U87 MG siCLIC1 and U87 MG CLIC1 
FLAG cells were analyzed by NTA. Neither CLIC1 
silencing nor CLIC1 overexpression in U87 MG cells 
had any effect on EV size distribution (Fig. 6A). Also, the 
yield of EVs secreted by U87 MG cells with modulated 
CLIC1 expression was identical to that of EVs produced 
by control cells (Fig. 6B). Notably, the abundance of either 
Figure 4: CLIC1-containing EVs enhance GBM growth in vivo. U87 MG cells were incubated with EVs (1 μg/ml) derived 
from U87 MG NT, U87 MG siCLIC1 and U87 MG CLIC1 FLAG cells and subcutaneously injected into one flank of nude mice (n = 30 
animals per group). As controls, untreated U87 MG cells were injected as well. Average tumor volumes at the indicated time points were 
measured. B. Tumors that formed after treatments described in A were surgically resected and weighted. Three independent experiments 
were performed. Error bars in A represent standard errors; solid lines in B are median values while error bars stand for minimum and 
maximum values. GLM tests of between-subjects effects showed statistically significant difference for the relative tumor growth according 
to the time, the treatment, and the interaction between those two variables. *p < 0.05.
Table 1: U87 MG cells were treated with NT EVs, siCLIC1 EVs and CLIC1 FLAG EVs and 
intracranially injected into nude mice (n = 10 animals per group). 
Treatment
Engrafted tumors
1st week 3rd week
veichle 2/10 9/10
NT EVs 5/10 8/10
siCLIC1 EVs 1/10 2/10
CLIC1 FLAG EVs 8/10 10/10
As controls, untreated U87 MG cells were injected as well (n = 10). Tumor incidence was calculated.
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Figure 5: CLIC1 secreted protein resides in EVs released from GBM CSCs. A. Representative immunoblots showing the 
expression of CLIC1 in three different GBM CSCs and in their respective media. GAPDH was used as loading control. B. Size profile of 
GBM CSC-derived EVs measured by NTA. Shown is the profile from a representative experiment. C. hGBM#10 CSC whole cell lysates 
(WCL) and lysates from corresponding EVs were analysed for the indicated proteins by Western blotting. A representative immunoblot 
is shown. D. Whole cell lysates (WCL) obtained from control hGBM#10 CSCs (NT) and CLIC1 silenced hGBM#10 CSCs (siCLIC1), as 
well as lysates of corresponding EVs, were analysed by Western blotting using antibodies against CLIC1, and the EV markers CD63 and 
tsg101. A representative immunoblot is shown. E. hGBM#10 CSCs were cultured in presence of EVs (50 μg/ml) derived from either NT 
or siCLIC1 hGBM#10 CSCs for 120 hours and assessed for cell growth by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide 
(MTT) assay. Three independent experiments were performed; error bars represent standard error; *p < 0.05.
Table 2: GBM CSCs were treated with their own NT EVs and siCLIC1 EVs, and intracranially 
injected into nude mice (n = 10 animals per group at the early time point analyzed, n = 5 animals 
per group at the end point of the experiment). 
Treatment
Engrafted tumors
2nd week 4th week
NT EVs 6/10 4/5
siCLIC1 EVs 3/10 5/5
Tumor incidence was calculated.
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smaller vesicles (under 50 nm) or larger vesicles (ranging 
in size from 50 to 100 nm or larger then 100 nm) was 
not affected by CLIC1 modulation (Fig. 6C). Comparable 
results were obtained by analyzing EVs derived from 
T98G cells (Fig. S7) or from GBM CSC samples 
(Fig. S8). Moreover, CLIC1 modulation did not induce 
marked alterations in the expression of the canonical 
exosome markers CD63 or tsg101 either in EV samples 
(Fig. 3A, 5D and S6) or in GBM cells (Fig. S9). These 
data show that CLIC1 modulation in GBM cells does 
not affect EV phenotypic features, biogenesis or release 
of EVs. In addition, PKH26-labeled EVs from control, 
CLIC1-silenced and CLIC1-overexpressing U87 MG 
cells were equally taken up, thus excluding the possibility 
that the different proliferative response could be due to 
differences in EV uptake efficiency (Fig. 6D). Next, we 
used shotgun proteomics to determine the global protein 
composition of NT EVs, siCLIC1 EVs and CLIC1 FLAG 
EVs purified from U87 MG cells and thus assess whether 
differences in protein content could account for alteration 
in the proliferative response of GBM cells. We obtained 
a total of 2642, 2310 and 2328 proteins from NT EVs, 
Figure 6: EV size and yield are not affected by CLIC1 modulation in GBM cells. A. Size distribution of EVs shedded by 
U87 MG NT, U87 MG siCLIC1 and U87 MG CLIC1 FLAG cells, measured by NTA. B. The yield of EVs shedded by U87 MG NT, U87 
MG siCLIC1 and U87 MG CLIC1 FLAG cells, measured by NTA. C. EVs were divided into three different dimensional classes, and their 
abundance was measured by NTA. A-C data are from a representative experiment. D. EVs derived from U87 MG NT, U87 MG siCLIC1 
and U87 MG CLIC1 FLAG cells were labelled with PKH26 dye, and added to U87 MG recipient cells for 24 hours. EV uptake efficiency 
was expressed as percentage of PKH26 positive cells measured at different time points. Two-way ANOVA. Contribution of “treatment” and 
“time”: *p < 0.05. Results shown in B-D represent mean ± standard errors from three independent experiments.
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siCLIC1 EVs and CLIC1 FLAG EVs, respectively 
(Fig. S10A and Supplementary Table 1). The proteomes of 
NT EVs, siCLIC1 EVs and CLIC1 FLAG EVs annotated 
upon high-resolution LCMSMS analysis are highly 
overlapping (Fig. S10B) and GO analysis did not reveal 
major alterations in EV protein content (Fig. S10C), thus 
reinforcing the idea that the pro-proliferative response 
induced by CLIC1 FLAG EVs can be mostly ascribed 
to CLIC1.
DISCUSSION
Cancer development and progression depends 
on intercellular communication within cancer cells and 
between cancer cell and the surrounding stroma. Apart 
from direct cell-cell interactions and classical paracrine 
signals, extracellular vesicles (EVs) have emerged as a 
novel mediator of such intercellular communication by 
inducing multiple biological responses, i.e. tumor growth, 
tumor cell invasion and metastasis, angiogenesis, immune 
system response and drug resistance.
GBM cells adopt EV-mediated communication 
either to sustain their own proliferative and invasive 
potential or to modulate surrounding cell behaviour in 
order to promote tumor growth.
Here we provide evidence for the first time that 
Chloride Intracellular Channel 1 (CLIC1) protein, apart 
from its intracellular role, exists also as a secreted protein, 
released by GBM cells, either cell lines or patient-derived 
CSCs. Moreover, we demonstrate that its release occurs 
via EVs, and CLIC1 maintains its activity within EVs, 
i. e. modulating EV-mediated GBM cell proliferation in a 
CLIC1-dependent fashion.
Different lines of evidence support CLIC1 protein 
secretion by GBM cells. By biochemical approaches 
we detected CLIC1 protein in GBM cell culture media; 
moreover, by directly tracking exogenous CLIC1 protein 
(i.e. FLAG-tagged form of CLIC1 protein) in vitro, we 
demonstrated that CLIC1 protein can be secreted by a 
GBM donor cell and can efficiently enter into a different 
GBM recipient cell.
A significant part of secreted proteins exploits 
endoplasmic reticulum (ER)/Golgi pathway in order to 
be released in the extracellular environment. To do that, 
a target protein has to show a specific signal peptide 
that fates it to the exocytic pathway [39]. CLIC1 is 
not endowed with such region and it is synthetized by 
cytosolic ribosomes [40]. Thus, CLIC1 protein might 
exploit mechanisms of export alternative to canonical 
ER/Golgi secretion pathways [41]. This evidence is even 
strengthened by the lack of any colocalization between 
CLIC1 and ER/Golgi/lysosome markers [42].
The main trait of CLIC1 protein resides in its dual 
nature as a soluble globular cytoplasmic protein and as 
an integral membrane protein endowed with ion channel 
activity. The vast majority of CLIC1 protein is kept in 
the cytoplasm in its soluble form, as demonstrated by 
digitonin extraction: digitonin-resistant CLIC1 is either 
plasma membrane-bound or bound to cytosolic vesicles 
[42]. Moreover, CLIC1 vesicular localization is endorsed 
by CLIC1 expression pattern itself, which is dotted and 
scattered throughout the cell as reported in different 
human cell lines (PancI, HeLa, macrophages) [40, 42, 
43]. Similarly, we observed that CLIC1 is expressed 
either at the plasma membrane or in punctate cytoplasmic 
structures in GBM cells ([20] and our unpublished data). 
The above observations prompted us to investigate the 
EV-mediated mechanism of CLIC1 protein release. GBM 
cell lines and primary human GBM samples release EVs 
in vitro [8] and in vivo [44]. Thus, we isolated EVs from 
cell culture media of either GBM cell lines and GBM 
CSCs by serial ultracentrifugation [34]. Sample purity 
was assessed by: (1) western immunoblot, showing 
a significant enrichment of the common endocytic 
markers CD63 and tsg101, (2) Nanoparticle Tracking 
Analysis proving that purified vesicle size fall in the 
50–150 nm range, (3) EM analysis proving that EV 
samples comprise morphologically heterogeneous, 
bilayer-enclosed vesicles expressing CD63 protein. 
Interestingly, we found CLIC1 protein expressed in GBM 
cell-derived EVs in association with typical exosomal 
proteins, as demonstrated by western immunoblot, 
immune-EM and PLA technique. Supporting this finding, 
CLIC1 protein expression was documented within EVs 
released by a plethora of cell types and biological fluids 
[24, 25, 29–31]. In addition, CLIC1 is listed as a top-
scored protein in ExoCarta database. Of further interest, 
CLIC1 protein was recently found circulating in human 
serum or plasma, and proposed as a potential biomarker in 
nasopharyngeal [21] and ovarian carcinoma [22]. CLIC1 
primary structure harbors a PPXY motif, recognized by the 
WW domain of the Nedd4 E3 ubiquitin-ligase [45, 46], 
and two dileucine motifs that are thought to support its 
enrollment into endocytic pathway [47, 48]. Considering 
that ubiquitination represents a major signal triggering the 
recruitment of ESCRT machinery and cargo incorporation 
within EVs [49, 50], the two structural hints existing in 
CLIC1 protein sequence, together with our biochemical 
data showing ubiquitinated CLIC1 in GBM cells, foster 
CLIC1 expression within EVs isolated by human GBM 
cells.
Recently, we have demonstrated that CLIC1 
expression is associated with poorer prognostic GBMs, 
and its inhibition, by silencing its expression or blocking 
its channel activity, regulates GBM progression by 
targeting GBM CSCs properties [20].
EVs have been shown to sustain tumor growth 
in a variety of model systems, including GBM [8]. 
Interestingly, treatment of GBM cells with CLIC1-
containing EVs stimulates cell growth both in vitro and 
in vivo. Either CLIC1 silencing or CLIC1 overexpression 
in GBM cells result in the secretion of EVs with reduced 
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or increased CLIC1 protein content, respectively. Notably, 
EVs derived from CLIC1-overexpressing GBM cells 
accelerate cell growth in vitro and tumor engraftment 
in vivo. By contrast, these stimulations are significantly 
attenuated by GBM cell treatment with EVs that contained 
reduced CLIC1 protein content. However, modulation 
of CLIC1 protein expression in GBM cells does not 
significantly modify EV secretion or uptake, suggesting 
that the observed phenotype depends on EV molecular 
cargo modifications. Of note, proteomic approach 
reveals no major differences other than CLIC1 in EV 
protein cargo.
Our findings comprehensively suggest that CLIC1 
is secreted within GBM cell-derived EVs, where it is 
involved in regulating EV-mediated pro-tumorigenic 
response. Of note, GBM is a heterogeneous tumor 
hierarchically organized, containing a small fraction of 
CSCs, responsible for tumor maintenance, progression 
and resistance to therapy, and giving rise to the bulk of 
malignant differentiated cells [51, 52]. Interestingly, both 
GBM cell lines and GBM CSCs are equally responsive 
to the treatment of EVs carrying distinct level of CLIC1 
protein. Thus, it is conceivable that the CLIC1 pro-
tumorigenic phenotype described previously [20] might 
rely also on CLIC1 circulating fraction other than CLIC1 
cytoplasmic levels. Secreted CLIC1 protein may support 
tumor proliferation by (i) directly mediating the expansion 
of tumor cells, either bulk differentiated cells or CSCs, and 
(ii) molding tumor microenvironment. However, further 
studies are required in order to clarify how CLIC1 protein 
contained in EVs contributes to tumor microenvironment 
remodeling. [53]
MATERIALS AND METHODS
Extensive description of cell culture conditions, EV 
isolation, western blotting analysis, nanoparticle tracking 
analysis, electron microscopy, as well as functional in vitro 
and in vivo assays, is provided in Supplementary Material.
Human GBM samples
This study was approved by the Ethical Committee 
for human experimentation of IEO (European Institute of 
Oncology) and all patients signed an approved consent 
document prior to surgery. Surgical specimens of tumors 
were collected at the Neurosurgery Dpt. at IRCCS Istituto 
Clinico Humanitas and examined by a neuropathologist 
to verify that each case met criteria for GBM and to 
select a tissue fragment with high content of viable 
tumor tissue. Each tissue specimen was dissociated into 
single cell suspension and maintained as neurospheres in 
growth factors supplemented DMEM-F12 1:1 medium, 
as previously described [38]. Human GBM cell lines 
U87MG, A172, LN405, U118MG, T98G, DBTRG-05MG 
and U373 MG were purchased from American Type 
Culture Collection (ATCC) and maintained in DMEM 
(Lonza) supplemented with 2 mM glutamine, 100 U/mL 
penicillin and 100 μg/mL streptomycin, and 10% FBS. All 
cell cultures were maintained at 37°C in a humidified 5% 
CO2 incubator.
Isolation of extracellular vesicles
GBM cells were grown in in serum-free medium 
for 48 hours prior to EV isolation. The media were then 
collected and processed according to standard procedures 
[34]. Briefly, media underwent serial centrifugation 
(500 g for 10’, 1200 g for 20’, 10000 g for 30’), they 
were filtered with a 0.22-μm pore filtersyringe, and 
then ultracentrifuged at 100000 g for 60’. The resulting 
pellet was washed in PBS before ultracentrifugation at 
100000 g for 60’.
Electron microscopy (EM)
For routine electron microscopy (EM), 
purified EVs were fixed with 1% glutaraldehyde 
for 1 hour, washed, post-fixed with 1% reduced 
osmium tetroxide for 1 hour, washed, post-stained 
with 0,3% thiocarbohydrazide; refixed in the OsO4 and 
embedded into Epon. Ultrathin sections were placed on 
formvar-coated grids or slot-grids. Immune-EM analysis 
was performed as previously described [54, 55].
Nanoparticle tracking analysis (NTA)
We used the light-scattering characteristics of 
488 nm laser light on EVs preparations undergoing 
Brownian motion injected by continuous flow into the 
sample chamber of an LM10 unit (Nanosight, Amesbury, 
UK). Three videos of 60–90 seconds were recorded of 
each sample. Data analysis was performed with NTA 
3.0 software (Nanosight). The diffusion coefficient and 
hydrodynamic radius were determined using the Stokes–
Einstein equation, and results were displayed as a particle 
size distribution. Data are presented as the average and 
standard deviation of the three video recordings. Since 
NTA is most accurate between particle concentrations 
in the range of 2 × 108 to 2 × 109/ml, when samples 
contained higher numbers of particles, they were diluted 
before analysis and the relative concentration calculated 
according to the dilution factor. Control 100 and 200 nm 
beads were supplied by Nanosight. NTA of a small 
sample of any given preparation revealed that they 
were essentially monodisperse, excluding the problem 
of aggregation, which may significantly impact on a 
biological system.
Proximal ligation assay (PLA) 
Samples were processed for PLA according to 
manufacturer’s instructions (OLink Bioscience, Sweden) 
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using the DuoLink in situ Orange detection reagent. 
Primary antibodies employed for PLA were: CD63 (mouse 
monoclonal, 1:50, clone FC-5.01 18–7300 Invitrogen), 
CLIC1 (rabbit polyclonal, 1:500, sc-134859 Santa Cruz, 
CA, USA).
Western blot analysis
Primary antibodies: CLIC1 (mouse monoclonal, 
1:1000, clone H-48, sc-134859, Santa Cruz, CA, 
USA), Vinculin (mouse monoclonal, 1:10000, clone 
HVIN-1, Sigma Aldrich, St. Louis, MO), CD63 (mouse 
monoclonal, 1:50, clone FC-5.01 18-7300 Invitrogen), 
tsg101 (goat polyclonal, 1:1000, sc-6037 Santa Cruz, 
CA,USA), GM130 (mouse monoclonal, 1:500, 610822, 
Becton Dickinson, Franklin Lakes, NJ, USA).
In vitro cell growth
U87 MG were harvested in 96-well plates at the 
density of 5000 cells. Growth curves were determined by 
counting the cell numbers 72, 96 and 120 hours after EV 
administration.
GBM CSCs were harvested at a density of 3000 cells 
per well in 50 μl and treated with 50 μg/ml EVs. Cell 
viability was assessed after 120 hours of incubation. 
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide (MTT, 50 mg/ml) was added and, after incubation 
for 4 hours, crystals were dissolved in DMSO. Cell 
viability was evaluated by CellTiter 96® AQueous Non-
Radioactive Cell Proliferation Assay (Promega, Madison, 
WI). Three independent replicates were considered for 
each experiment.
Animal experiments
Experiments involving animals were performed 
in accordance with the Italian Laws (D.L.vo 116/92 and 
following additions), which enforces EU 86/609 Directive 
(Council Directive 86/609/EEC of 24 November 1986 on 
the approximation of laws, regulations and administrative 
provisions of the Member States regarding the protection 
of animals used for experimental and other scientific 
purposes).
CD-1 nude mice (5 weeks old, Charles River 
Laboratories) were inoculated via s.c. injection on the 
dorsal region with U87 MG cells (2.5 ~ 106 in 150 μl of 
PBS) with or without EVs (1 μg/ml). Tumor mass was 
determined by caliper, measured in two perpendicular 
diameters and calculated using the formula 1/2a × b2, 
where a stands for the long diameter and b is the short 
diameter. Mice were sacrificed and tumors were collected 
for further analysis. For the intracranial orthotopic model 
(38), GBM cells (either U87 MG cells or GBM CSCs) 
were resuspended in 2 μl of PBS with or without EVs 
(1 μg/ml), and stereotaxically injected into the nucleus 
caudatus (coordinates: 0.7 - 1 mm posterior, 3 mm left 
lateral, 3.5 mm in depth from the dura) of 5 weeks 
old CD-1 nude mice. The mice were maintained until 
development of neurologic signs and then killed for tumor 
areas analysis using ImageJ software.
Statistical analysis
Statistical analysis was performed using Statistical 
Package for Social Science (SPSS) software. Statistical 
significance of differences for all parametric variables has 
been tested by means of analysis of variance (ANOVA) 
with Bonferroni’s correction. Data are graphed as mean ± 
standard error from at least three independent experiments. 
Differences were considered statistically significant when 
P was less than .05.
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